Publications by authors named "David G Spencer"
Article Synopsis
- Locteron is a new formulation of recombinant interferon-alpha2b designed for controlled release, tested on 27 volunteers with various dosages compared to pegylated interferon and placebo.
- Serum levels of IFN-alpha2b from Locteron remained high for up to 14 days, with a longer elimination half-life than pegylated interferon.
- Locteron showed fewer and milder side effects like flu-like symptoms compared to pegylated interferon, suggesting it could be a promising treatment for hepatitis C with bi-weekly dosing.